GlassScriptPhysician profile
Marcus Cain Daniels
NPI 1962072363
$5,893.26
in general payments reported to CMS, 2019-2025
22 companies · $2,106 in 2025
The $2,106 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $106 · 2023: $2,371 · 2024: $1,310 · 2025: $2,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,707 · Travel and Lodging: $1,032 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,706.67 |
| Travel and Lodging | $1,032.15 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $1,482.00 | 2023 | Neurostar Tms Therapy System |
| Abbvie INC. | $1,260.81 | 2022-2025 | |
| Corium, LLC | $569.12 | 2023-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $402.34 | 2024-2025 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $366.42 | 2022-2025 | Caplyta |
| Alkermes, INC. | $319.91 | 2022-2025 | Lybalvi, Aristada, Vivitrol |
| Axsome Therapeutics, INC. | $281.91 | 2023-2025 | Auvelity |
| Lundbeck LLC | $199.76 | 2022-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $168.88 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $155.85 | 2024-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $110.71 | 2023-2024 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $110.02 | 2024-2025 | Spravato |
| Vanda Pharmaceuticals INC. | $94.91 | 2024-2025 | Fanapt, Hetlioz |
| Almatica Pharma LLC | $71.72 | 2024-2025 | Loreev Xr |
| Teva Pharmaceuticals USA, INC. | $67.92 | 2025 | Austedo Xr |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $52.16 | 2023-2025 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $50.80 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $37.46 | 2025 | Xelstrym |
| Harmony Biosciences LLC | $35.16 | 2024-2025 | |
| Brainsway USA INC | $22.21 | 2025 | Deep Tms System |
| Neurocrine Biosciences, INC. | $19.03 | 2023 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $14.16 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Daniels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.